Guardant Health (NASDAQ:GH) Announces Quarterly Earnings Results

Guardant Health (NASDAQ:GH) posted its quarterly earnings data on Thursday. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15), Zacks reports. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. Guardant Health updated its FY 2025 guidance to EPS.

Guardant Health Price Performance

Guardant Health stock traded down $1.60 during trading hours on Thursday, hitting $47.40. The stock had a trading volume of 3,021,831 shares, compared to its average volume of 2,470,453. The stock has a market capitalization of $5.86 billion, a price-to-earnings ratio of -11.18 and a beta of 1.32. Guardant Health has a 1-year low of $15.81 and a 1-year high of $50.89. The stock’s fifty day moving average is $39.78 and its two-hundred day moving average is $31.39.

Insider Buying and Selling at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares in the company, valued at $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders sold 2,652 shares of company stock worth $93,192. 5.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on GH. JPMorgan Chase & Co. increased their price objective on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Barclays began coverage on Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target for the company. Guggenheim reissued a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. The Goldman Sachs Group upped their price objective on shares of Guardant Health from $36.00 to $49.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Finally, Sanford C. Bernstein dropped their price target on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. Sixteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $42.63.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.